Company news

Design Therapeutics, Inc. news in 2025

Design Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Design Therapeutics to Participate in Upcoming Investor Conferences

November 26, 2025

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

November 5, 2025

Design Therapeutics Appoints Justin Gover to Board of Directors

September 10, 2025

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

August 27, 2025

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

August 7, 2025

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

June 4, 2025

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

May 28, 2025

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

May 13, 2025

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

May 7, 2025

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

May 1, 2025

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

April 21, 2025

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

April 17, 2025

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

March 10, 2025

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

March 3, 2025

Decks in 2025